HER2 and Cancer: Mechanism, Testing and Targeted Therapy

Sophie I. Williams (Editor)
Christopher E. Rogers (Editor)

Series: Cancer Etiology, Diagnosis and Treatments
BISAC: MED062000

Clear

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

The HER2 receptor is a 185-kDa transmembrane glycoprotein with tyrosine kinase activity, and belongs in the human epidermal growth factor receptor (HER) family consisting of four members. Moreover, aberrant HER2 protein overexpression has been linked to various human gynecological adenocarcinomas, including breast, endometrium, ovary and cervix, and has been found to be a poor prognostic factor for survival. This new book presents topical research in the study of HER2, including targeting HER2 with photodynamic therapy; HER2 shedding as a biomarker in breast cancer; development of trastuzumab resistance and targeted nanomedicines conjugated with HER2 antibodies in cancer therapy. (Imprint: Nova Biomedical )

Preface

1. Targeting HER2 with Photodynamic Therapy, PP.1-46
(Ján Kovaľ, Peter Solár, Jaromír Mikeš, Rastislav Jendželovský, Peter Fedoročko, Faculty of Sciences, Institute of Biology and Ecology, P. J. Šafárik University in Košice, Košice, Slovakia)

2. Investigating Molecular Mechanisms of Specificity in Regulation of the HER2 Receptor Tyrosine Kinase through Molecular Modeling and Simulation, pp.47-80
(Shannon E. Telesco, Andrew Shih, Yingting Liu, Ravi Radhakrishnan, Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA)
Free Download Available

3. The HER2 Shedding and its Consequences on Breast Cancer, pp.81-100
(Pierre-Jean Lamy, Anne-Sophie Gauchez, Chantal Tse, Department of Clinical Biology and Oncogenetic, Val d’Aurelle-Paul Lamarque Cancer Center , Montpellier, France, and others)

4. The Role of HER2 in Targeted Cancer Therapy and Hypothesized Future Perspectives. pp. 101-122
(Luca Monfregola, Stefania De Luca, Istituto di Biostructure e Bioimmagini IBB-CNR, Naples, Italy)

5. HER2 Positive Primary Breast Cancer in Older Women: Clinical Significance and Therapeutic Challenge, pp. 123-144
(B.M. Syed, R. Leonard, I.O. Ellis, K.L. Cheung, Divisions of Breast Surgery and Pathology, University of Nottingham, and Imperial College London, United Kingdom)

6. Influence of Psychological Stress on Initiation, Progression, Metastasis in Breast Cancer, pp.145-160
(Ming Shi, Lu Qian, Beifen Shen, Ning Guo, Department of Molecular Immunology, Institute of Basic Medical Sciences, Beijing, P.R. China)

7. Development of Trastuzumab Resistance: Is it Only in Signaling?
(Timothy Kute, John Stehle, Department of Pathology, Wake Forest University Baptist Medical Center, Winston Salem, North Carolina, and others)pp.161-174
Free Download Available

8. Targeted Nanomedicines Conjugated with HER2 Antibodies in Cancer Therapy, pp.175-186
(Jie Gao, Bohua Li, Wei Li, Jianxin Dai, Hao Wang, Yajun Guo, Cancer Institute of the Second Military Medical University, Shanghai, People’s Republic of China, and others)

9. Topoisomerase II-Alpha Index Predicts the Efficacy of Anthracycline-Based Chemotherapy for Breast Cancers, pp.187-200
(Kiyomi Taniyama, Nao Morii, Kazuya Kuraoka, Akihisa Saito, Toshinao Nishimura, Junichi Sakane, Mieko Harada, Miho Tanaka, Hiroyo Takahashi, Kazuaki Miyamoto, Hironori Kato, Institute for Clinical Research, Departments of Diagnostic Pathology, Breast Surgery and Surgery, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Kure, Japan)
Free Download Available

10. Role of Δ16HER2 Splice Variant in Breast Tumor Progression and Response to HER2-Targeted Therapy, pp.201-210
(Serenella M. Pupa, Manuela Campiglio, Anna Rossini, Rosaria Orlandi, Valentina Ciravolo, Augusto Amici, Elda Tagliabue, Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy, and others)
Free Download Available

11. Molecular Profiling of HER2-Related Protein Networks in Formalin-Fixed and Paraffin-Embedded Cancer Tissues, pp.211-216
(Daniela Berg, Karl-Friedrich Becker, Technische Universität München, Institut für Pathologie, Trogerstrasse, München, Germany)

12. HER2 & the ErbB Network pp.217-230
(Joel Kochanski, Mylin Torres and Ryan Ballenger)

Index

You have not viewed any product yet.